Abbott wins FDA approval for UltiSynq defibrillation lead
ABT•Abbott received FDA approval and CE Mark for its UltiSynq defibrillation lead, which provides conduction system pacing and defibrillation therapy for patients requiring both treatments.
1. Regulatory clearances
Abbott received FDA approval and CE Mark for its UltiSynq defibrillation lead, securing regulatory clearance in the United States and European Union. The lead delivers conduction system pacing and defibrillation therapy for patients requiring both treatments.
